Mitsubishi Tanabe Pharma makes proprietary prescription pharmaceuticals in a number of therapeutic areas, including cardiovascular disease, diabetes, neuroscience, immunology, and oncology. In its home market, it sells products such as anticoagulant Anplag, anti-allergy medicine Talion, liver drug Urso, and neuroprotective agent Radicut. Its Benesis unit makes therapeutic plasma proteins such as albumin. The company markets and sells its products through in-house sales agents and distributors. Formerly Mitsubishi Pharma, the company merged with fellow Japanese drugmaker Tanabe Seiyaku and subsequently changed its name; Mitsubishi Chemical Holdings owns a majority stake in the new entity.

Biovitrum company makes pharmaceuticals that treat hemophilia and autoimmune diseases like rheumatoid arthritis, scleroderma (hardening of the skin), and others. Its available products include arthritis drug Kineret and cancer side-effect drug Kepivance. Biovitrum company also has drugs for inflammatory diseases and absorption disorders in development in its pipeline. Biovitrum distributes its products to Europe, Australia, and the US through partnerships with pharmaceutical giants like Pfizer and Amgen.

NeuTec wants to make visiting the hospital an experience that lessens patient dangers. The biopharmaceutical company identifies and compares antibodies produced by patients who recover from infections (acquired in hospitals) to those produced by patients who die. Then, using its FabTec technology, it develops genetically recombinant antibodies, or "grabs," to treat patients with life-threatening infections. The company's two leading candidates, Mycograb, which targets a fungus in the mouth and skin, and Aurograb, which targets bacterial infections, are in clinical trials in the UK. Mycograb also is in clinical trials in the US.

Abbott Laboratories company was founded in 1888 and is based in Abbott Park, Illinois. Abbott Laboratories manufactures and sells health care products worldwide. Abbott company's Pharmaceutical Products segment offers adult and pediatric pharmaceuticals for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis, Crohn's disease, dyslipidemia, HIV infection, hypothyroidism, advanced prostate cancer, endometriosis and central precocious puberty, anemia caused by uterine fibroids, obesity, epilepsy and bipolar disorder, migraines, and secondary hyperparathyroidism; and provides anesthesia products and anti-infectives. Its Diagnostic Products segment offers immunoassay systems; chemistry systems; assays used for screening and/or diagnosis for drugs of abuse, cancer, therapeutic drug monitoring, fertility, physiological diseases, and infectious diseases; instruments that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infections agents; genomic-based tests; hematology systems and reagents; and point-of-care diagnostic systems and tests for blood analysis.Abbott Company's Nutritional Products segment provides various forms of prepared infant formula and follow-on formula, adult and other pediatric nutritional products, nutritional products used in enteral feeding in health care institutions, and bars and nutritional brands. Its Vascular Products segment offers coronary, endovascular, and vessel closure devices, such as drug-eluting coronary stent systems, coronary metallic stents, balloon dilatation products, coronary guidewires, vessel closure devices, and carotid stent systems to treat vascular disease. Abbott serves wholesalers, government agencies, health care facilities, specialty pharmacies, independent retailers, hospitals, clinics, physicians' offices, blood banks, commercial laboratories, alternate-care testing sites, plasma protein therapeutic companies, and third-party distributors.

CyDex Pharmaceuticals, Inc. company was founded in 1993 and is based in Lenexa, Kansas. CyDex Pharmaceuticals, Inc., a pharmaceutical company, engages in the development and commercialization of drugs specifically designed to address limitations of current therapies. It develops a portfolio of product candidates utilizing its drug formulation technology using Captisol, a group of cyclodextrins. The company’s products include Geodon IM and Abilify Injection IM for bipolar disorder/schizophrenia; Vfend IV for antifungal; and Cerenia for canine motion sickness. It also develops Fosphenytoin IV and IM for status epilepticus; Melphalan IV for multiple myeloma; Topiramate IV for epilepsy; Amiodarone IV for arrhythmia; Budesonide Solution Inhalation for asthma; Clopidogrel IV for atherothrombosis; and Budesonide/Azelastine Nasal Spray for allergic rhinitis. In addition, the company out license its technology to third parties for use in the development of their products. CyDex Pharmaceuticals, Inc. was formerly known as CyDex, Inc. and it changed its name in November 2007.

Collegium Pharmaceutical's wisdom is in developing over-the-counter and prescription drugs for a variety of conditions affecting the skin and central nervous and respiratory systems. Typically the company starts with existing drugs and works to improve them through new delivery systems that modify their release, or prevent abuse. It is working with drugs to treat such conditions as fibromyalgia, pain, and sleep apnea. Through its subsidiary Onset Therapeutics, the company markets wound care and dermatology (acne, skin infections) drugs. Its topical aerosol product Exactacain is licensed and sold by Healthpoint while its approved allergy nasal spray AllerNaze is licensed to Lupin Ltd.

VioQuest Pharmaceuticals, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of clinical stage drug therapies targeting both the molecular basis of cancer and side effects of cancer treatment. The Company’s lead compound under development is Xyfid (1% topical uracil) for the treatment and prevention of Hand-Foot Syndrome (HFS). In parallel, Xyfid is also being developed to treat dry skin conditions and manage the burning and itching associated with various diseases of the skin or dermatoses. In addition, VioQuest Pharmaceuticals is developing VQD-002 (triciribine phosphate monohydrate or TCN-P), a small molecule anticancer compound that inhibits activation of protein kinase B (PKB or AKT), a key component of a signaling pathway known to promote cancer cell growth and survival, as well as resistance to chemotherapy and radiotherapy. On July 16, 2007, the Company completed the sale of Chiral Quest, Inc. to Chiral Quest Acquisition Corp.

Synta Pharmaceuticals Corp., a biopharmaceutical company, focuses on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. It has a global partnership with Roche for developing novel CRACM inhibitors, an oral calcium released activated calcium modulator ion channel inhibitor program that is in the lead optimization stage for the treatment of autoimmune diseases. The company also retains rights in various indications and markets to its other drug candidates and programs, which include STA-9090, an Hsp90 inhibitor that is in Phase 1 development; elesclomol, an oxidative stress inducer for the treatment of cancer; and apilimod, an oral IL-12/23 inhibitor, which is in Phase 2 for rheumatoid arthritis. In addition, Synta Pharmaceuticals Corp. is developing STA-9584, a vascular disrupting agent that is in preclinical development. The company was incorporated in 2000 and is based in Lexington, Massachusetts.

IS Pharma, formerly known as Maelor, is a UK-based drug and medical device company focused on products for the hospital market; it sells directly in the UK and uses distributors elsewhere. Among its products are Volpex, Haemopressin, and ISOplex, all critical care products used in surgery; Mysoline, an oral treatment for epilepsy; and Cryogesic and Aloxi, two cancer drugs. Maelor outlicenses some products outside its core focus areas to other firms, including its OptiFlo catheter, which is distributed by C.R. Bard. Previously limited primarily to the UK market, the firm bought Swiss drug firm Specialty European Pharma International in 2008, giving it a wider presence in Europe and in North America.

Roche Diagnostics Corporation company was founded in 1998 and is headquartered in Indianapolis, Indiana. Roche Diagnostics Corporation operates as a subsidiary of Roche Holding AG. Roche Diagnostics Corporation offers diagnostic tests and systems. The company operates in the diagnostic areas of diabetes care, centralized diagnostics, applied science, molecular diagnostics, and point-of-care diagnostics. Its products include diagnostics tools that test for congestive heart failure, HIV, Hepatitis B and C, fertility, and diabetes diseases. The company supplies its products to researchers, physicians, patients, hospitals, and laboratories. It has facilities in Indiana, New Jersey, South Carolina, Colorado, New Hampshire, Puerto Rico, and California, as well as locations in Canada.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.